CDKN2A and neoplasm: As an additional analysis, we analyzed the proportion of tumors with homozygous loss of CDKN2A/B (a clinically relevant marker in these tumors), showing a higher proportion in cluster 2 consistent with the higher overall tumor grade in this cluster (Fig. 5e).